Nomura Holdings’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$27.5M Buy
109,358
+97,566
+827% +$21M 0.03% 287
2026
Q1
$2.56M Sell
11,792
-24,575
-68% -$5.45M 0.01% 845
2025
Q4
$8.31M Sell
36,367
-21,342
-37% -$4.86M 0.01% 601
2025
Q3
$13.4M Buy
57,709
+30,058
+109% +$6.12M 0.02% 426
2025
Q2
$5.13M Sell
27,651
-11,637
-30% -$2.16M 0.01% 571
2025
Q1
$8.23M Sell
39,288
-38,259
-49% -$7.44M 0.02% 535
2024
Q4
$13.8M Buy
77,547
+51,784
+201% +$9.52M 0.02% 420
2024
Q3
$5.09M Sell
25,763
-17,026
-40% -$3.18M 0.01% 648
2024
Q2
$7.34M Buy
42,789
+16,349
+62% +$2.71M 0.01% 554
2024
Q1
$4.81M Sell
26,440
-22,297
-46% -$3.84M 0.01% 650
2023
Q4
$7.55M Buy
48,737
+43,763
+880% +$6.38M 0.02% 529
2023
Q3
$741K Sell
4,974
-14,590
-75% -$2.14M ﹤0.01% 1049
2023
Q2
$2.64M Buy
+19,564
New +$2.87M 0.01% 651
2023
Q1
Sell
-1,754
Closed -$268K 1412
2022
Q4
$284K Buy
+1,754
New +$269K ﹤0.01% 1055
2022
Q3
Sell
-53,481
Closed -$7.67M 1653
2022
Q2
$8.22M Sell
53,481
-32,517
-38% -$4.97M 0.03% 404
2022
Q1
$14M Sell
85,998
-103,337
-55% -$15M 0.04% 271
2021
Q4
$25.6M Buy
189,335
+13,865
+8% +$1.64M 0.07% 219
2021
Q3
$19.1M Buy
175,470
+133,039
+314% +$15.2M 0.05% 229
2021
Q2
$4.78M Buy
42,431
+23,201
+121% +$2.61M 0.01% 591
2021
Q1
$2.08M Sell
19,230
-55,311
-74% -$5.92M ﹤0.01% 848
2020
Q4
$7.99M Buy
74,541
+31,936
+75% +$3.07M 0.01% 480
2020
Q3
$3.73M Buy
42,605
+39,413
+1,235% +$3.71M 0.01% 533
2020
Q2
$313K Buy
+3,192
New +$281K ﹤0.01% 946
2019
Q4
Sell
-1,570,924
Closed -$130M 1075
2019
Q3
$115M Buy
1,570,924
+1,525,380
+3,349% +$105M 0.43% 40
2019
Q2
$3.34M Buy
45,544
+13,321
+41% +$1.05M 0.01% 578
2019
Q1
$2.6M Sell
32,223
-27,210
-46% -$2.23M 0.01% 599
2018
Q4
$5.47M Buy
59,433
+35,077
+144% +$3.08M 0.02% 474
2018
Q3
$2.31M Sell
24,356
-54,822
-69% -$5.2M 0.01% 691
2018
Q2
$7.34M Sell
79,178
-74,853
-49% -$7.31M 0.02% 433
2018
Q1
$14.6K Buy
154,031
+32,753
+27% +$3.6M 0.03% 322
2017
Q4
$13.7M Buy
121,278
+12,995
+12% +$1.22M 0.02% 378
2017
Q3
$9.62M Sell
108,283
-59,625
-36% -$4.54M 0.02% 391
2017
Q2
$12.2M Buy
167,908
+72,469
+76% +$4.87M 0.03% 311
2017
Q1
$6.22M Sell
95,439
-56,438
-37% -$3.55M 0.02% 407
2016
Q4
$9.51M Buy
151,877
+99,805
+192% +$6.09M 0.02% 383
2016
Q3
$3.29M Sell
52,072
-9,603
-16% -$622K 0.01% 549
2016
Q2
$3.81M Sell
61,675
-27,905
-31% -$1.7M 0.01% 486
2016
Q1
$5.1M Sell
89,580
-33,145
-27% -$1.85M 0.02% 350
2015
Q4
$7.26M Sell
122,725
-127,893
-51% -$7.37M 0.02% 313
2015
Q3
$13.7M Buy
250,618
+157,093
+168% +$10.2M 0.05% 192
2015
Q2
$6.21M Buy
93,525
+33,416
+56% +$2.18M 0.02% 385
2015
Q1
$3.5M Sell
60,109
-345,484
-85% -$20.9M 0.01% 473
2014
Q4
$26.2M Buy
405,593
+212,436
+110% +$13.4M 0.07% 178
2014
Q3
$11.1M Buy
193,157
+180,012
+1,369% +$9.99M 0.03% 399
2014
Q2
$739K Sell
13,145
-298,968
-96% -$15.7M ﹤0.01% 1586
2014
Q1
$16M Buy
312,113
+175,092
+128% +$8.85M ﹤0.01% 335
2013
Q4
$7.23M Sell
137,021
-143,123
-51% -$7.03M 0.03% 301
2013
Q3
$12.5M Buy
280,144
+136,391
+95% +$6.05M 0.08% 210
2013
Q2
$5.97M Buy
+143,753
New +$6.29M 0.05% 278

Other funds holding ABBV

Nomura Holdings's ABBV Position: Q2 2026 in Review

Nomura Holdings increased its AbbVie (ABBV) stake by 827% in Q2 2026, buying an estimated $21M and bringing the position to 109,358 shares worth $27.5M. The position accounts for 0.03% of the portfolio, ranked #287.

Nomura Holdings first reported a position in ABBV in Q2 2013 and has held it in 49 quarters since. The position peaked at $115M in Q3 2019. 4,063 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Nomura Holdings held 109,358 shares of AbbVie worth $27.5M as of Q2 2026.
  • Nomura Holdings bought 97,566 AbbVie shares in Q2 2026, an estimated $21M.
  • AbbVie made up 0.03% of Nomura Holdings's portfolio in Q2 2026, its #287 holding.
  • Nomura Holdings first reported a position in AbbVie in Q2 2013 and has held it in 49 quarters since.
  • Nomura Holdings's AbbVie position peaked at $115M in Q3 2019.
  • 4,063 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.